In February 2026, FDA published a draft guidance describing a plausible mechanism framework for developing individualized therapies. Some readers have asked whether the Plausible Mechanism Guidance opens a door for a patient’s own stored fat cells. This post explains what the draft says, which products it targets, and why it changes nothing for banked adipose tissue.
TLDR The Plausible Mechanism Guidance is a February 2026 FDA draft for individualized therapies that target a specific genetic cause of a severely debilitating or life threatening disease, mainly genome editing and RNA based products. It is a draft, not a rule. It does not mention adipose tissue, stem cells, autologous products, or SVF, and it leaves the Part 1271 criteria untouched. Banking adipose tissue does not guarantee access to any future therapy under this or any other pathway.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease, including rare genetic conditions. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently has FDA approval for any condition. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
A reader sends a link to an FDA press release about accelerating individualized therapies and asks a fair question. If FDA is willing to weigh a plausible mechanism as part of the evidence for a new product, does that help a person whose own fat cells sit in storage?
The short answer is no. The draft describes a way to develop one kind of product for one kind of patient, and autologous adipose cells are not that product. This post walks through the draft’s own words so the reader can see the boundaries without taking anyone’s word for it. Nothing here is legal advice, and a final version may read differently. What will not change because of this draft is the federal rule that governs banked adipose tissue today.
What Is the Plausible Mechanism Guidance?
The Plausible Mechanism Guidance is a draft FDA guidance titled “Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause,” issued by CBER and CDER in February 2026 under Docket FDA-2026-D-1256. The guidance page on fda.gov lists it as a draft.
The timeline is short. FDA announced the draft in a press release on February 23, 2026. The Federal Register notice ran on February 25, 2026, and comments were due April 27, 2026.
The phrase itself came earlier. A 2025 commentary by FDA leadership in the New England Journal of Medicine, titled “FDA’s New Plausible Mechanism Pathway,” appears in the December 11, 2025 issue at pages 2365 to 2367 and is indexed on PubMed. It is a commentary, not a study, and it carries no data on any product.
Which Products Does the Draft Target?
The draft targets individualized therapies for specific genetic conditions with a known biological cause, and it names genome editing and RNA based therapies as its examples. Its scope sentence reads: “While this guidance specifically discusses genome editing (GE) and RNA-based therapies (e.g., antisense oligonucleotides (ASOs)), the general concepts may apply to other types of individualized therapies.”
The definition is narrower than the word “individualized” might suggest. The draft says individualized therapies “target a specific pathophysiologic abnormality serving as the root cause of a disease, for example, specific pathogenic genetic variant(s) causing a severely debilitating or life-threatening disease or condition in a small number of patients where a randomized controlled trial typically is not feasible.”
FDA’s press release frames the reach the same way. It says the framework “may apply to additional tailored therapeutics provided they directly address the underlying specific cause of the disease.” The common thread is a product built against a named root cause, for a patient population too small to run a standard trial.
What the Draft Does Not Cover
The draft does not name autologous adipose products, and it does not change the criteria in 21 CFR Part 1271. The full text, available as a PDF from FDA, contains no reference to cell therapy, autologous products, adipose tissue, stem cells, or SVF. That silence follows from the definition. A patient’s own stored fat is tissue recovered from that patient, not a product designed against a named genetic variant, and nothing in the draft describes it.
The federal rule for that tissue sits elsewhere. Under section 1271.10, an HCT/P is regulated solely under section 361 only if it meets all four criteria: it is minimally manipulated, it is intended for homologous use only, it is not combined with another article except water, crystalloids, or a sterilizing, preserving, or storage agent, and it either has no systemic effect and does not depend on the metabolic activity of living cells or is for autologous, relative, or reproductive use.
The two defined terms in that test are explained on this site. The minimally manipulated criterion and the homologous use criterion both come from definitions in section 1271.3. The February 2026 draft does not amend either definition, and it does not propose to.
How the Plausible Mechanism Guidance Fits With the May 2026 CMC Final Guidance
Both 2026 documents concern how new products are developed, and neither touches the section 361 criteria. In May 2026, CBER issued “Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application; Guidance for Industry,” Docket FDA-2026-D-4692, which fda.gov shows as final. This site covered it in a separate post on the CMC flexibility guidance.
The CMC guidance page states that it “describes how FDA applies flexibility to the chemistry, manufacturing, and controls (CMC) requirements for human cellular and gene therapy (CGT) products being developed for biologics license applications (BLAs).” It adds that it “applies only to CGT products regulated by the Center for Biologics Evaluation and Research (CBER).”
The table below places the two guidances side by side. They differ in status and subject but share one boundary: both address product development, not how a 361 HCT/P is judged.
| Guidance | Issued | Status on fda.gov | What it covers |
|---|---|---|---|
| Plausible Mechanism Framework for individualized therapies (draft) | February 2026, CBER and CDER, Docket FDA-2026-D-1256 | Draft; comments were due April 27, 2026 | Evidence considerations for individualized therapies aimed at a specific genetic root cause; genome editing and RNA based examples |
| CMC Flexibilities for human cellular and gene therapy products (final) | May 2026, CBER, Docket FDA-2026-D-4692 | Final, Level 2; page updated July 7, 2026 | How FDA applies flexibility to CMC requirements for CGT products headed to a BLA; CBER regulated products only |
A reader who sees either document cited as proof that FDA has loosened the rules for stored fat should ask which section of the text says so. Neither one does.
What It Means for Someone With Banked Tissue
For a person with banked adipose tissue, the Plausible Mechanism Guidance changes nothing. Any future use of that tissue still runs through the same framework it did before February 2026, and the four criteria in section 1271.10(a) still decide whether an HCT/P is regulated solely under section 361.
No adipose-derived stem cell product currently has FDA approval for any condition. Adipose cells fall outside the scope of this draft, and any decision about research participation belongs with a licensed provider who knows the patient. Banking preserves the patient’s own tissue. It does not enroll anyone in a study, and it does not create eligibility for a pathway the draft never describes.
Questions about expanded access and post-trial access are among the most common ones readers bring to this site. Those questions have their own answer, covered in the post on expanded access programs, and that answer does not change with this draft either.
The practical takeaway is about expectations. No guidance, draft or final, promises a future use for banked tissue. If a bank or a clinic tells you that a 2026 FDA document opened a path for your cells, ask for the page and paragraph, then read it against the definition quoted above.
Frequently Asked Questions
Is the Plausible Mechanism Guidance a final rule?
No. It is a draft guidance, listed as draft on fda.gov, with a comment period that closed April 27, 2026. It does not amend 21 CFR Part 1271.
Does the draft mention stem cells or adipose tissue?
No. The draft contains no reference to cell therapy, autologous products, adipose tissue, stem cells, or SVF. Its examples are genome editing and RNA based therapies aimed at specific genetic variants.
Could my banked fat qualify under this pathway?
The draft does not describe stored autologous tissue, so there is no basis to say it could. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit from any pathway. Any future use depends on FDA regulatory status at that time and on the guidance of a licensed physician.
Key Takeaways
The Plausible Mechanism Guidance is a February 2026 FDA draft, Docket FDA-2026-D-1256, for individualized therapies that target a specific genetic root cause of a severely debilitating or life threatening disease in a small number of patients. Its examples are genome editing and RNA based therapies. It does not mention adipose tissue, stem cells, autologous products, or SVF, and it does not amend the four criteria in section 1271.10(a). Like the May 2026 CMC final guidance, which covers products headed to a BLA, it leaves Part 1271 unchanged. For a person with banked tissue, nothing changes, and no expectation of future access should rest on it.
Save My Fat connects patients and providers with a U.S.-based tissue bank. It is not a tissue bank, a laboratory, a medical practice, or a treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, California, Georgia, and Tennessee governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Readers weighing adipose tissue banking for potential future use can review current pricing or bring their regulatory questions to the contact page.
Save My Fat works with a U.S.-based tissue bank for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Please consult your own licensed healthcare provider before making any decisions about treatment or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: FDA adipose tissue regulation.
